AstraZeneca PLC (AZN)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$0.09
-15.70%
HEALTHCARE · Cap: $118,580
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 613575% more annual revenue ($60.44B vs $9.85M). AZN leads profitability with a 17.2% profit margin vs -10.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
WOK
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for WOK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Grey zone — moderate risk
Smaller company, higher risk/reward
ROE of -5.8% — below average capital efficiency
Revenue declined 14.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while WOK is a turnaround play — different risk/reward profiles.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 35/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a prominent player in the medical technology sector, focusing on the research, development, and commercialization of innovative healthcare solutions. With a strong emphasis on advanced medical devices, the company strives to improve patient outcomes and tackle significant challenges in global healthcare. Its dedication to quality, innovation, and a diverse product portfolio not only enhances its market position but also aligns with the interests of institutional investors seeking opportunities in transformative healthcare advancements. As the demand for effective medical technologies continues to rise, WORK is well-positioned for sustained growth and value creation.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?